Cosette Pharmaceuticals

Latest news

• AMAG Pharmaceuticals Announces FDA Approval of Vyleesi (bremelanotide injection) for Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
  21 June 2019
• Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
  4 June 2018
• Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
  26 March 2018
• Once-Daily Welchol (colesevelam HCl) for Oral Suspension Receives FDA Approval To be Mixed With Fruit Juice or Diet Soft Drinks
  25 July 2011
• FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
  26 July 2010
• FDA Approves Benicar for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16
  11 February 2010
• Welchol (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
  7 October 2009
• Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
  10 July 2009
• Public Citizen: Antiplatelet Medication Is Unsafe, Should Not Be Approved,Says Scientist Who Helped Develop the Drug
  3 June 2009
• Azor Receives FDA Approval as First-Line Treatment for High Blood Pressure
  13 May 2009

Drugs Associated with Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 42 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.